Clinical trial NCT02947750: Neurovascular Transduction During Exercise in Chronic Kidney Disease
Official title: Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Renal Insufficiency, Chronic
Keywords: Hypertension
Kidney Disorder
Nephrology
Physiology
Lead sponsor: Emory University
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2016-10-28
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate). This study will also test whether or not regular exercise on a bicycle and/or treatment with 6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures during exercise. 6R-BH4 is currently FDA-approved for use in patients with certain forms of a disease called phenylketonuria, but it is not currently FDA approved for blood pressure or exercise capacity in people with CKD.

Detailed description: The major problem addressed in this study is to understand mechanisms underlying poor exercise capacity in patients with chronic kidney disease (CKD). Prior research has found that CKD patients have an exaggerated increase in blood pressure during certain forms of exercise that could contribute to exercise dysfunction as well as cardiovascular disease. This study will test the mechanisms underlying this exaggerated blood pressure response, as well as the potential benefits of simple measures such as exercise training on a stationary bicycle, and treatment with 6R-BH4, a drug that is currently FDA-approved for the treatment of phenylketonuria, but has been shown to have beneficial effects on vascular health in patients with kidney disease. This study will also examine the effects of exercise with histidine and beta-alanine supplementation. Histidine and beta-alanine are two over-the-counter supplements commonly used to enhance sports performance in athletes.

Prior to the intervention portion of this study, the researchers will measure how much the vein constricts in response to adrenaline in CKD patients versus controls. The study will also measure muscle pH, and muscle oxygenation during exercise in CKD patients and controls.

The intervention portion of the study will test whether aerobic exercise training with and without 6R-BH4, or with and without histidine and beta-alanine supplementation might help muscle pH and adrenaline levels, vascular reactivity, muscle oxygenation, and the exaggerated blood pressure response during exercise in CKD patients. Participants will be randomized using a 2x2 factorial design to exercise training (ET) with 6R-BH4, ET with placebo, stretching (control condition to exercise) with 6R-BH4, and stretching with placebo. Participants will undergo exercise training on a stationary bicycle, or stretching exercises, 3 times per week for 6-14 weeks (depending on availability of the participant).

Eligibility criteria: Inclusion Criteria for Chronic Kidney Disease Patients:

* Stage III or IV Chronic Kidney Disease, defined as reduction in estimated glomerular filtration rate (eGFR) to 15-59 cc/minute as calculated by the modified Modification of Diet in Renal Disease (MDRD) Study equation or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
* Stable renal function, with no greater than a 30% reduction in eGFR over the prior 3 months
* Does not exercise regularly (defined as exercising less than 20 minutes twice per week)
* Willing and able to cooperate with the study protocol

Inclusion Criteria for Control Study Participants:

* Does not exercise regularly (defined as exercising less than 20 minutes twice per week)
* Willing and able to cooperate with the study protocol

Exclusion Criteria:

* severe CKD (eGFR\<15 cc/minute)
* ongoing drug or alcohol abuse
* diabetic neuropathy
* any serious systemic disease that might influence survival
* severe anemia with hgb level \<9 g/dL
* clinical evidence of congestive heart failure or ejection fraction below 35%
* symptomatic heart disease determined by prior electrocardiogram, stress test, and/or history
* treatment with central alpha agonists (clonidine)
* uncontrolled hypertension with BP greater than 170/100 mm Hg
* low blood pressure with BP less than 100/50
* pregnancy or plans to become pregnant
* current treatment with monoamine oxidase (MAO) inhibitors
* inability to exercise on a stationary bicycle

Primary outcomes:
measure: Change in functional sympatholysis
timeFrame: Baseline, Week 12
measure: Change in vascular alpha 1 adrenergic responsiveness
timeFrame: Baseline, Week 12
measure: Change in exaggerated pressor responses during exercise
timeFrame: Baseline, Week 12
Secondary outcomes:
measure: Renal artery resistance during exercise
timeFrame: Baseline, Week 12
measure: Change in endothelial function
timeFrame: Baseline, Week 12
measure: Change in vascular stiffness
timeFrame: Baseline, Week 12
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Emory University Hospital Midtown
state: Georgia
city: Atlanta
country: United States
facility: Emory University Hospital
state: Georgia
city: Decatur
country: United States
facility: Atlanta VA Health Care System
state: Georgia
Study officials:
affiliation: Emory University
name: Joe Nocera, PhD
role: PRINCIPAL_INVESTIGATOR
References: